C4 Therapeutics Inc Cash Flow-to-Debt Ratio
C4 Therapeutics Inc cash flow-to-debt ratio. C4 Therapeutics Inc (CCCC) has a Cash Flow-to-Debt Ratio of -0.01x as of June 2026, meaning its operating cash flow of $-1.57 Million could theoretically repay 0% of its total liabilities ($112.14 Million) in one year. See C4 Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of C4 Therapeutics Inc (2018–2025)
Cash flow-to-debt ratio of C4 Therapeutics Inc from 2018 to 2025. Historical debt coverage capacity for C4 Therapeutics Inc across 8 annual periods. Check CCCC cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
C4 Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2018–2025)
C4 Therapeutics Inc cash flow-to-debt ratio by year from 2018 to 2025. Year-by-year debt coverage analysis for C4 Therapeutics Inc. For the full cash flow conversion analysis, see C4 Therapeutics Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.96x | $-98.69 Million | $102.49 Million | ▼ -97.5% |
| 2024 | -0.49x | $-65.16 Million | $133.62 Million | ▲ +40.5% |
| 2023 | -0.82x | $-106.84 Million | $130.34 Million | ▼ -9.6% |
| 2022 | -0.75x | $-105.94 Million | $141.61 Million | ▼ -0.8% |
| 2021 | -0.74x | $-86.97 Million | $117.16 Million | ▼ -31.7% |
| 2020 | -0.56x | $-67.25 Million | $119.35 Million | ▼ -333.3% |
| 2019 | 0.24x | $55.61 Million | $230.22 Million | ▲ +421.8% |
| 2018 | -0.08x | $-16.98 Million | $226.24 Million | — |